Zansecimab
Based on 1 Customer Validation
Zansecimab (LY-3127804) is a monoclonal antibody against angiopoietin 2 (Ang‑2). Zansecimab can be used in research on angiogenesis, immunomodulation and anti-tumor activity.
For research use only. We do not sell to patients.
- Purity : ≥95.0%
- CAS No.: 2415205-37-5
- Molecular Weight:145.24 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2415205-37-5
-
Appearance Liquid
-
Molecular Weight 145.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Zansecimab]
-
Synonyms
LY-3127804
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Martin-Liberal J, et al. First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. Br J Cancer. 2020 Oct;123(8):1235-1243. [Content Brief]
[2]. Yen CC, et al. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf. 2022 Feb;21(2):157-166. [Content Brief]
[3]. Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5;910:174500. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zansecimab Related Classifications
HY-P99510 Related Classifications
Powered by Bioz